Artis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA Strategy
Artis BioSolutions today announced the appointment of Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer, effective February 9, 2026. Dr. Broderick will lead scientific strategy, advocacy and innovation initiatives across the Artis platform, supporting the company’s mission to build an integrated ecosystem for the development and manufacturing of next-generation genetic medicines.
Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology
Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies (“Syngoi”), a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies.
